MX2020004050A - Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. - Google Patents

Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina.

Info

Publication number
MX2020004050A
MX2020004050A MX2020004050A MX2020004050A MX2020004050A MX 2020004050 A MX2020004050 A MX 2020004050A MX 2020004050 A MX2020004050 A MX 2020004050A MX 2020004050 A MX2020004050 A MX 2020004050A MX 2020004050 A MX2020004050 A MX 2020004050A
Authority
MX
Mexico
Prior art keywords
linagliptin
crystalline
preparation
structural formula
novel
Prior art date
Application number
MX2020004050A
Other languages
English (en)
Spanish (es)
Inventor
Venkata Raghavendracharyulu Palle
Shanmughasamy Rajmahendra
Dharshan Jakkali Chandregowda
Thangarasu Ponnusamy
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2020004050A publication Critical patent/MX2020004050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020004050A 2017-09-27 2018-09-27 Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. MX2020004050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (1)

Publication Number Publication Date
MX2020004050A true MX2020004050A (es) 2020-11-06

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004050A MX2020004050A (es) 2017-09-27 2018-09-27 Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina.

Country Status (10)

Country Link
US (1) US11040974B2 (cg-RX-API-DMAC7.html)
JP (1) JP2020535193A (cg-RX-API-DMAC7.html)
KR (1) KR20200092946A (cg-RX-API-DMAC7.html)
CN (1) CN111511743A (cg-RX-API-DMAC7.html)
AU (1) AU2018343236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076980A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004050A (cg-RX-API-DMAC7.html)
RU (1) RU2020114890A (cg-RX-API-DMAC7.html)
WO (1) WO2019064214A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
IN2013MU02055A (cg-RX-API-DMAC7.html) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
JP2020535193A (ja) 2020-12-03
BR112020005964A2 (pt) 2020-10-06
WO2019064214A1 (en) 2019-04-04
KR20200092946A (ko) 2020-08-04
US11040974B2 (en) 2021-06-22
US20200354363A1 (en) 2020-11-12
RU2020114890A (ru) 2021-10-27
CA3076980A1 (en) 2019-04-04
CN111511743A (zh) 2020-08-07
AU2018343236A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
CO2017001884A2 (es) Polimorfos de selinexor
HUE057926T2 (hu) Eljárás tiokarbonátok elõállítására
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
MX384201B (es) Proceso para la preparacion de treprostinil.
WO2018029711A3 (en) Process for the preparation of venetoclax
EP3404006A4 (en) PROCESS FOR PREPARING TRANS-1-CHLORO-3,3,3-TRIFLUORPROPENE
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EP3483137A4 (en) PROCESS FOR THE PRODUCTION OF 1-CHLORO -1,2-DIFLUOROETHYLENE
BR112017006116A2 (pt) processos de preparação de compostos e compostos
GEP20227382B (en) Anti-coagulation factor xi antibodies
WO2016035007A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2016013162A (es) Proceso para la fabricacion de medicamentos.
HUE059501T2 (hu) Aminopirimidin származékok elõállításához alkalmas intermedierek, eljárás elõállításukra, és eljárás aminopirimidin származékok elõállítására azok alkalmazásával
IT201600105178A1 (it) Procedimento per la produzione di dieni
MX2017000467A (es) Nuevo proceso para la purificacion de rhu-gcsf.
EA202090980A1 (ru) Синтез антибактериальных аминогликозидных аналогов
UA117779C2 (uk) Піразини як модулятори gpr6
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
WO2016024284A3 (en) A process for the preparation of mirabegron and its intermediates
MX2020012065A (es) Compuestos de ciclopentano.
EP3789493A4 (en) PROCESS FOR PRODUCTION OF CELLOOLIGOSACCHARIDE
CL2018002149A1 (es) Proceso.